Week in Review: BeiGene Options DualityBio ADC in $1.3 Billion Agreement

Deals and Financings

• Beijing’s BeiGene optioned global rights to a next-gen ADC candidate targeting solid tumor cancers from DualityBio of Shanghai in a $1.3 billion agreement;
• WuXi Biologics, a global biologic drug CRDMO, will spin-off its biologics/small molecule bioconjugates subsidiary and conduct a $500 million Hong Kong IPO of the business;
• Guangdong Sinotau Pharmaceuticals raised $152 million in its sixth funding to support its portfolio of novel diagnostic and therapeutic radiopharmaceuticals;
• Zhejiang Doer Biologics of Hangzhou out-licensed global rights for one of its portfolio candidates to Germany’s BioNTech, the mRNA COVID vaccine company;
• Suzhou GeneQuantum Healthcare expanded its collaboration with Aimed Bio, a South Korean biotech, adding five ADC candidates for unmet needs to the partnership;
• Biosyngen, a cell and gene therapy company, established the Guangzhou-Singapore Technology Innovation and Translational Medicine Center to develop innovative cancer drug candidates;
• Beijing InnoCare will collaborate with ArriVent, a Philadelphia area biopharma, to test a combination drug regimen for advanced non-small cell lung cancer;

Trials and Approvals

• Shanghai Fosun Pharma reported its NDA filing for tenapanor, a therapy that lowers blood serum phosphorus in dialysis patients, was accepted for review in China;
• Connect Biopharma, a Taicang-San Diego inflammatory disease company, presented four posters describing the progress of rademikibart, the company’s lead drug, in atopic dermatitis patients;
• 280Bio, a US subsidiary of Shanghai Yingli Pharma, was approved to start US trials of a small molecule inhibitor of RAS signaling for tumors that are KRAS-resistant.
  
  Share this with colleagues: